CRISPR Therapeutics AG (MEX:CRSP) Short-Term Capital Lease Obligation : MXN265 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Short-Term Capital Lease Obligation?

CRISPR Therapeutics AG's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN265 Mil.

CRISPR Therapeutics AG's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (MXN261 Mil) to Dec. 2023 (MXN265 Mil) and increased from Dec. 2023 (MXN265 Mil) to Mar. 2024 (MXN265 Mil).

CRISPR Therapeutics AG's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (MXN249 Mil) to Dec. 2022 (MXN309 Mil) but then declined from Dec. 2022 (MXN309 Mil) to Dec. 2023 (MXN265 Mil).

CRISPR Therapeutics AG Short-Term Capital Lease Obligation Historical Data

The historical data trend for CRISPR Therapeutics AG's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Short-Term Capital Lease Obligation Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

160.10

226.01

249.41

308.86

265.22

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															283.30	254.30	261.30	265.22	265.41

CRISPR Therapeutics AG Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

CRISPR Therapeutics AG Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (MEX:CRSP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CRSP:USA 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.